Business Trends– category –
-
Amkor to Invest $7 Billion in Arizona for Advanced AI Chip Packaging, Shifts Korean SiP Production to Vietnam
Seeking Alpha USA Overview Amkor Technology is making a monumental $7 billion investment to construct an advanced packaging and test campus in Arizona, slated for production by early 2028, to address the escalating demand for AI chips. T... -
TSMC Moves to Large-Format Glass Substrates with CoPoS to Address CoWoS Capacity for AI Chips, Targeting 2028-2029 Mass Production
36Kr, Semiconductor Industry Watch, AI Weekly Taiwan Overview TSMC has launched a pilot line for its CoPoS (Chip-on-Panel-on-Substrate) advanced packaging at Taiwan's VisEra, aiming to alleviate the critical CoWoS capacity bottleneck for... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
Focused Ultrasound and Microbubbles Temporarily Open Blood-Brain Barrier for Enhanced Brain Drug Delivery
Drug Target Review UK Overview The blood-brain barrier (BBB) obstructs most therapeutic agents from reaching the brain, a major hurdle in treating neurological disorders. Researchers are advancing focused ultrasound (FUS), specifically l... -
Kymera Therapeutics’ Oral STAT6 Degrader KT-621 Shows Positive Phase 1b Atopic Dermatitis Data, Potential Injectable Alternative
TradingView Global Overview Kymera Therapeutics' lead candidate, KT-621 (an oral STAT6 degrader leveraging targeted protein degradation), demonstrated positive Phase 1b data in atopic dermatitis. Presented at the American Academy of Derm... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e... -
Imperial College Develops Prostate-Targeted mRNA Nanogels, Overcoming Liver Accumulation in Cancer Therapy
Imperial College London UK Overview Researchers at Imperial College London have developed prostate-targeted degradable polymer nanogels for mRNA delivery in prostate cancer treatment. This innovation overcomes the challenge of tissue-spe... -
Bambusa Therapeutics’ Bispecific Antibody BBT001 Achieves Rapid, Durable Itch Relief and AD Improvement in Phase 1 Atopic Dermatitis Trial
Dermatology Times USA Overview Preliminary Phase 1 clinical data for Bambusa Therapeutics' bispecific antibody BBT001 shows rapid and sustained improvement in disease severity and pruritus in moderate-to-severe atopic dermatitis (AD) pat... -
Dove Medical Press Reviews Exosome-Inspired Nanocarriers: Next-Gen Drug Delivery for Cancer Therapy
Dove Medical Press UK Overview Dove Medical Press published a review on exosomes as next-generation bio-derived drug delivery systems for cancer therapy. The review emphasizes exosomes' natural ability to cross biological barriers and th...
